

Quarterly Activities Report and Appendix 4C


HIGHLIGHTS

- During Q3 FY2026, sales of \$3 million reflected seasonal respiratory testing rates in Australia
- Strong balance sheet with \$25.7 million in cash and term deposits on 31 March 2026
- Implemented organisational restructuring and cost savings to improve operational efficiency with estimated annual cost reduction of \$5 million from FY2027
- Signed a ten-year term agreement (extendable by two twelve-month periods) with Hvidovre Hospital in Denmark for the supply of equipment and reagents for the testing of 28,000 clinical samples in year one with an estimated 3% annual growth

Operational Update

The Company recorded sales of \$3.0 million (unaudited) for Q3 FY2026. Revenue for the quarter reflected seasonal respiratory testing rates in Australia.

Figure 1: GSS Quarterly revenue (A\$M)



Receipts from customers for the quarter were \$3.7 million. Net operating cash outflow was \$3.5 million. Net investing cash outflows of \$0.3 million for the quarter included investments in equipment for placement at customer sites and within the Company's product validation facility. Payments of fees to Directors, including the CEO, were \$0.3 million for the quarter and are included in 1.2(e) Staff Costs in the Appendix 4C.

As of 31 March 2026, Genetic Signatures held a total cash balance of \$25.7 million, comprising \$17.7 million in cash at bank and \$8.0 million in term deposits. While term deposits are classified as 'other financial assets' in the Annual Report, in accordance with accounting standards, they have been included in 'cash and cash equivalents' in the Appendix 4C, to reflect funds available to the Company for future operating activities.

Organisational Restructuring with Estimated Annualised Cost Reduction of \$5 million from FY2027

Following a comprehensive strategic review, the Company has implemented a significant organisational restructuring which resulted in 30 positions being made redundant across five divisions (*ASX Announcement 30 March 2026*). Concurrently, three new positions have been created focusing on project management and outsourcing capabilities. Further operational efficiencies have been identified which, together with the redundancies, are expected to result in estimated cost savings of \$5 million on an annualised basis from FY2027 onwards. One-off redundancy cash outflows, which included accrued leave balances, of \$0.8 million, were incurred in April 2026 and will be included in the Appendix 4C for Q4 FY2026.

Transition to Outsourced Product Development

During Q4 FY2026 the Company commenced transitioning elements of its product development to specialist contract research organisations, while maintaining core intellectual property and technical capabilities in-house (*ASX Announcement, 30 March 2026*). This model is intended to provide the Company with access to flexible, best-in-class product development while reducing fixed costs and improving speed to market. This restructuring prioritises development and commercialisation of differentiated molecular diagnostic products with multi-jurisdictional regulatory approvals and broad commercial scalability. The Company believes that its pragmatic product development strategy is essential to driving product adoption in priority geographies and market segments.

Danish Supply Agreement Signed with Hvidovre Hospital

In April 2026 the Company signed agreements for the supply of Equipment, Reagents and Consumables for Gastrointestinal Screening at Hvidovre Hospital, one of the leading public hospitals in Denmark, for the testing of 28,000 samples in the first year, with a 3% estimated growth annually (*ASX Announcements, 15 April 2026*). The Reagent and Consumables Supply Agreement has a ten-year term, extendable for up to two 12-month periods. A customary installation and validation process has commenced with commercial orders expected from September 2026. The contract, combined with the outcomes of utilising the *EasyScreen™* tests in the UK and other markets, demonstrates that the Company's pan-enteric approach delivers measurable, real-world benefits for laboratories, clinicians, and ultimately patients and signals of growing momentum for broader adoption of the platform across Europe and globally.

CEO's Investor Briefing

The Company will hold an investor briefing in early June 2026 following the completion of the CEO Maria Halasz's first 90 days in office. Maria will present the Company's progress since her appointment and on focus areas for future growth. The briefing will present the outcomes of a comprehensive strategic review across all aspects of the business, including human resources, operational structure, the Company's key markets of Australia, the United States, Europe, and other identified growth opportunities. Maria will discuss plans to reset the US operations, while continuing to build on the momentum established across the EMEA business. The investor briefing will address opportunities to

scale organically and through strategic partnerships, as well as the Company's assessment of new markets that align with its core capabilities.

Outlook

The Company is operating in a highly competitive environment. This, coupled with the unknown severity of the Australian flu season, are factors which could have an impact on Q4 FY2026 revenues. Despite this, in Q3 FY2026 the Company has extended the term and scope of a supply agreement with a key Australian customer and remains focused on delivering new opportunities across the sales pipeline.

Focussed on advancing its EasyScreen™ molecular diagnostic platform across both its established markets and targeted growth geographies, the Company is actively assessing its commercial strategy and the most effective pathways for market development. With its organisational restructure well advanced, a product portfolio with regulatory approvals in major jurisdictions, a highly skilled and committed senior team, and strong balance sheet, the Company is focused on commercial partnerships that will enable it to scale into new market opportunities. The Company is well positioned to pursue this objective and is committed to delivering long term shareholder value.

– END –

Announcement authorised by Genetic Signatures' Board of Directors

For further information, see our website (www.geneticsignatures.com) or contact us:

Maria Halasz
Chief Executive Officer

maria.halasz@geneticsignatures.com

T: +61 (0) 2 9870 7580

Daniel Ireland
Investor Relations

daniel.ireland@datair.com.au

0428 607 884

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics company, specialising in detecting infectious diseases, using patented **3base®** technology to simplify the genetic complexity of pathogen identification. Automated diagnostic workflows accurately screen for multiple infectious pathogens with similar symptoms, in a single test. Genetic Signatures' unique solutions enable laboratories to enhance diagnostic workflow and efficiencies, while reducing costs. Rapid results support infection control, appropriate patient management and disease surveillance, improving healthcare outcomes. Genetic Signatures continues to expand its global presence with direct representation in Australia, the United States and Europe, alongside international distribution partnerships.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

GENETIC SIGNATURES LIMITED

ABN

30 095 913 205

Quarter ended ("current quarter")

31 March 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	3,657	13,827
1.2 Payments for		
(a) research and development	(654)	(1,999)
(b) product manufacturing and operating costs	(2,265)	(5,972)
(c) advertising and marketing	(101)	(745)
(d) leased assets	(69)	(262)
(e) staff costs	(3,644)	(11,338)
(f) administration, corporate and other costs	(1,086)	(3,090)
1.3 Dividends received (see note 3)		
1.4 Interest received	413	1,127
1.5 Interest and other costs of finance paid	(10)	(38)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	222	4,604
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(3,537)	(3,886)
2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(340)	(939)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(340)	(939)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Principal element of lease payments	(116)	(349)
3.10	Net cash from / (used in) financing activities	(116)	(349)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	29,690	30,873
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,537)	(3,886)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(340)	(939)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(116)	(349)
4.5	Effect of movement in exchange rates on cash held	(2)	(4)
4.6	Cash and cash equivalents at end of period	25,695	25,695

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	17,695	17,190
5.2	Call deposits	8,000	12,500
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	25,695	29,690

6. Payments to related parties of the entity and their associates

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

**Current quarter
\$A'000**

277

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

7.1 Loan facilities

7.2 Credit standby arrangements

7.3 Other (please specify)

7.4 **Total financing facilities**

Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000

7.5 **Unused financing facilities available at quarter end**

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (Item 1.9)	(3,537)
8.2 Cash and cash equivalents at quarter end (Item 4.6)	25,695
8.3 Unused finance facilities available at quarter end (Item 7.5)	-
8.4 Total available funding (Item 8.2 + Item 8.3)	25,695
8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	7.3

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 29 April 2026

Authorised by: Board of Directors

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.